Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study

BACKGROUND: Managements for refractory proficient mismatch repair (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC) were still challenging and controversial. Our study sought to investigate the efficacy and safety of anti-programmed cell death protein 1 (anti-PD-1) antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Rong-Rong, Yin, Xian-Li, Zeng, De-Yu, Shao, Feng-Jiang, Yamamoto, Seiichiro, Liu, Wu, Liu, Zhen-Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469175/
https://www.ncbi.nlm.nih.gov/pubmed/36111036
http://dx.doi.org/10.21037/atm-22-3690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469175/
https://www.ncbi.nlm.nih.gov/pubmed/36111036
http://dx.doi.org/10.21037/atm-22-3690

Ejemplares similares